(Updates)
** Shares of drugmaker Eyenovia EYEN.O fall 69.8% to
record low of 10 cents
** Co to discontinue a late-stage study for its experimental
drug-device combination after it failed the main goal of slowing
the progression of the condition
** Co was testing the drug to treat pediatric progressive
myopia that causes near-sightedness in early childhood, which
worsens as the person grows
** Says an independent committee reviewed the safety and
efficacy data from 252 trial participants and found that the
rate of myopia progression was not significantly different
between the treatment arm and placebo
** "We plan to terminate the study, review the data more
thoroughly, and evaluate next steps"- EYEN
** Says it is evaluating its strategic options, which may
include a business combination, reverse merger, asset sales or a
combination of those alternatives
** "Given the negative results, and the company's capital
constraints, we are downgrading shares in Eyenovia to Market
Perform" - brokerage William Blair
** Including session moves, stock down 94.8% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))